- Home
- IMOS vs NEO Comparison
IMOS vs NEO Comparison
Compare IMOS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMOS | NEO |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2007 | 2008 |
Fundamental Metrics
Financial Performance| Metric | IMOS | NEO |
|---|---|---|
| Price | $57.27 | $17.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 69.7K | ★ 1.8M |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.75 | $10.63 |
| Revenue Next Year | $4.21 | $9.73 |
| P/E Ratio | $158.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.33 | $7.07 |
| 52 Week High | $78.35 | $19.76 |
Technical Indicators
Market Signals| Indicator | IMOS | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 60.82 |
| Support Level | $55.07 | $15.72 |
| Resistance Level | $60.67 | N/A |
| Average True Range (ATR) | 1.79 | 0.75 |
| MACD | 0.45 | 0.05 |
| Stochastic Oscillator | 74.21 | 47.03 |
Price Performance
Historical ComparisonAbout IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.